Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.

Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M.

J Gynecol Oncol. 2019 Nov;30(6):e94. doi: 10.3802/jgo.2019.30.e94.

2.

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

Tumori. 2019 Aug 26:300891619868009. doi: 10.1177/0300891619868009. [Epub ahead of print]

PMID:
31446882
3.

Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma.

Indini A, Di Guardo L, Cimminiello C, De Braud F, Del Vecchio M.

Am J Clin Oncol. 2019 Aug;42(8):643-648. doi: 10.1097/COC.0000000000000566.

PMID:
31261257
4.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.

PMID:
31171878
5.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.

Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608.

PMID:
31095039
6.

Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture.

Auricchio R, Mandile R, Del Vecchio MR, Scapaticci S, Galatola M, Maglio M, Discepolo V, Miele E, Cielo D, Troncone R, Greco L.

Gastroenterology. 2019 Aug;157(2):413-420.e3. doi: 10.1053/j.gastro.2019.04.004. Epub 2019 Apr 9.

PMID:
30978358
7.

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis.

Galli G, Cavalieri S, Di Guardo L, Cimminiello C, Nichetti F, Corti F, Garcia MA, Pappalardi B, Fallai C, de Braud F, Platania M, Del Vecchio M.

Oncol Res Treat. 2019;42(4):186-194. doi: 10.1159/000497211. Epub 2019 Mar 5.

8.

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.

Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E223. doi: 10.3390/cancers11020223.

9.

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521. doi: 10.1007/s00432-018-2819-x. Epub 2018 Dec 11.

PMID:
30539281
10.

Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.

Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, Randon G, Tolomio E, De Braud F, Del Vecchio M.

Melanoma Res. 2019 Jun;29(3):289-294. doi: 10.1097/CMR.0000000000000539.

PMID:
30520799
11.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
12.

Ipsilateral somatosensory responses in humans: the tonic activity of SII and posterior insular cortex.

Del Vecchio M, Caruana F, Sartori I, Pelliccia V, Lo Russo G, Rizzolatti G, Avanzini P.

Brain Struct Funct. 2019 Jan;224(1):9-18. doi: 10.1007/s00429-018-1754-6. Epub 2018 Sep 20.

PMID:
30238209
13.

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.

Mennini FS, Bini C, Marcellusi A, Del Vecchio M.

Clin Drug Investig. 2018 Oct;38(10):967-976. doi: 10.1007/s40261-018-0690-9. Review.

PMID:
30143953
14.

Cutaneous melanoma in adolescents and young adults.

Indini A, Brecht I, Del Vecchio M, Sultan I, Signoroni S, Ferrari A.

Pediatr Blood Cancer. 2018 Nov;65(11):e27292. doi: 10.1002/pbc.27292. Epub 2018 Jul 3. Review.

PMID:
29968969
15.

Meyerson's phenomenon in melanoma: when a halo dermatitis hides a malignancy.

Piccolo V, Russo T, Del Vecchio M, Mascolo M, Argenziano G.

G Ital Dermatol Venereol. 2018 Jun;153(3):434-435. doi: 10.23736/S0392-0488.17.05536-5. No abstract available.

PMID:
29766703
16.

Models for governing relationships in healthcare organizations: Some empirical evidence.

Romiti A, Del Vecchio M, Grazzini M.

Health Serv Manage Res. 2018 May;31(2):85-96. doi: 10.1177/0951484818762014. Epub 2018 Mar 16.

PMID:
29546784
17.

Global network centrality of university rankings.

Guo W, Del Vecchio M, Pogrebna G.

R Soc Open Sci. 2017 Oct 4;4(10):171172. doi: 10.1098/rsos.171172. eCollection 2017 Oct.

18.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
19.

The Effect of Gluten-free Diet on Clinical Symptoms and the Intestinal Mucosa of Patients With Potential Celiac Disease.

Mandile R, Discepolo V, Scapaticci S, Del Vecchio MR, Maglio MA, Greco L, Troncone R, Auricchio R.

J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):654-656. doi: 10.1097/MPG.0000000000001745.

PMID:
28922261
20.

Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report.

Cavalieri S, Di Guardo L, Cossa M, Cimminiello C, Del Vecchio M.

J Clin Diagn Res. 2017 Jul;11(7):XD06-XD08. doi: 10.7860/JCDR/2017/26881.10200. Epub 2017 Jul 1.

21.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

22.

Systematic Review and Meta-analysis of Seizure Recurrence After a First Unprovoked Seizure in 815 Neurologically and Developmentally Normal Children.

Garcia Pierce J, Aronoff S, Del Vecchio M.

J Child Neurol. 2017 Nov;32(13):1035-1039. doi: 10.1177/0883073817726461. Epub 2017 Sep 7. Review.

PMID:
28879801
23.

Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma.

Franceschini D, Franzese C, De Rose F, Navarria P, D'Agostino GR, Comito T, Tozzi A, Tronconi MC, Di Guardo L, Del Vecchio M, Scorsetti M.

Br J Radiol. 2017 Aug;90(1077):20170257. doi: 10.1259/bjr.20170257. Epub 2017 Jul 14.

24.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.

25.

Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy.

Pessina F, Navarria P, Tomatis S, Cozzi L, Franzese C, Di Guardo L, Ascolese AM, Reggiori G, Franceschini D, Del Vecchio M, Bello L, Scorsetti M.

World Neurosurg. 2017 Sep;105:184-190. doi: 10.1016/j.wneu.2017.05.131. Epub 2017 May 31.

PMID:
28578123
26.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
27.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.

Ann Oncol. 2018 Feb 1;29(2):524. doi: 10.1093/annonc/mdx059. No abstract available.

PMID:
28379318
28.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M.

Lancet Oncol. 2017 May;18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27.

PMID:
28359784
29.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K.

Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

PMID:
28284557
30.

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.

Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P.

Cancer Biol Ther. 2016 Nov;17(11):1213-1220.

31.

Looking Is Not Seeing and Listening Is Not Hearing: A Replication Study With Accelerated BSN Students.

Honan L, Shealy S, Fennie K, Duffy TC, Friedlaender L, Del Vecchio M.

J Prof Nurs. 2016 Sep-Oct;32(5S):S30-S36. doi: 10.1016/j.profnurs.2016.05.002. Epub 2016 May 10.

PMID:
27659752
32.

Etiologies of hemoptysis in children: A systematic review of 171 patients.

Simon DR, Aronoff SC, Del Vecchio MT.

Pediatr Pulmonol. 2017 Feb;52(2):255-259. doi: 10.1002/ppul.23497. Epub 2016 Aug 29. Review.

PMID:
27575742
33.
34.

Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, Santoro A, Scorsetti M.

Cancer Treat Rev. 2016 Nov;50:1-8. doi: 10.1016/j.ctrv.2016.08.003. Epub 2016 Aug 18. Review.

PMID:
27566962
35.

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.

Cavalieri S, Di Guardo L, Cimminiello C, Bono A, Tolomio E, Colombetti A, Valeri B, Di Tolla G, de Braud F, Del Vecchio M.

Tumori. 2016 Oct 13;102(5):501-507. doi: 10.5301/tj.5000539. Epub 2016 Jul 27.

PMID:
27470608
36.

Differential Diagnosis in Pediatrics: A Probabilistic Approach.

Aronoff SC, Del Vecchio MT.

Hosp Pediatr. 2016 Aug;6(8):504-5. doi: 10.1542/hpeds.2016-0053. Epub 2016 Jul 12. No abstract available.

37.

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.

Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.

Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23.

38.

Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.

Ambrosio MR, Di Serio C, Danza G, Rocca BJ, Ginori A, Prudovsky I, Marchionni N, Del Vecchio MT, Tarantini F.

Diagn Pathol. 2016 May 25;11(1):45. doi: 10.1186/s13000-016-0495-1.

39.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.

Ann Oncol. 2016 Apr;27(4):732-8. doi: 10.1093/annonc/mdw016. Epub 2016 Jan 22. Erratum in: Ann Oncol. 2018 Feb 1;29(2):524.

PMID:
26802161
40.

Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.

Indini A, Di Nicola M, Del Vecchio M, De Braud F.

J Clin Oncol. 2016 Mar 20;34(9):1017-8. doi: 10.1200/JCO.2015.65.0028. Epub 2016 Jan 19. No abstract available.

41.

Spectrum of Clostridium difficile infections: Particular clinical situations.

Bouza E, Del Vecchio MG, Reigadas E.

Anaerobe. 2016 Feb;37:3-7. doi: 10.1016/j.anaerobe.2015.12.005. Epub 2015 Dec 15. Review.

PMID:
26700883
42.

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.

Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.

43.

Etiologies of asymptomatic microscopic hematuria in children - systematic review of 1092 subjects.

Clark M, Aronoff S, Del Vecchio M.

Diagnosis (Berl). 2015 Dec 1;2(4):211-216. doi: 10.1515/dx-2015-0020. Review.

PMID:
29540037
44.

Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects.

Gottesman LE, Del Vecchio MT, Aronoff SC.

BMC Pediatr. 2015 Nov 20;15:192. doi: 10.1186/s12887-015-0506-5. Review.

45.

Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach.

Ambrosio MR, Pirtoli L, del Vecchio MT.

Curr Drug Targets. 2016;17(3):266-75. Review.

PMID:
26477458
46.

Diagnosis of high risk multisistemic Langerhans cell histiocytosis: the practical use of cytology in dermatology.

Caccavale S, Del Vecchio M, Brancaccio G, Caccavale T, La Montagna M, Ruocco E.

G Ital Dermatol Venereol. 2016 Feb;151(1):124-5. Epub 2015 Oct 16. No abstract available.

PMID:
26474450
47.

Expression of Translationally Controlled Tumor Protein in Human Kidney and in Renal Cell Carcinoma.

Ambrosio MR, Rocca BJ, Barone A, Onorati M, Mundo L, Crivelli F, Di Nuovo F, De Falco G, del Vecchio MT, Tripodi SA, Tosi P.

Biomed Res Int. 2015;2015:730390. doi: 10.1155/2015/730390. Epub 2015 Sep 3.

48.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

49.

Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.

Ambrosio MR, Rocca BJ, Barone A, Ginori A, Crivelli F, Pirtoli L, Del Vecchio MT.

Anticancer Res. 2015 Oct;35(10):5595-600.

PMID:
26408731
50.

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Del Vecchio M, Ascierto PA, Mandalà M, Sileni VC, Maio M, Di Guardo L, Simeone E, Queirolo P.

Future Oncol. 2015;11(9):1355-62. doi: 10.2217/fon.15.55.

PMID:
25952781

Supplemental Content

Loading ...
Support Center